Skip to main content

Table 4 Multivariate analysis for OS and PFS of patients treated with or without rituximab

From: Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients

ParameterOverall survivalP valueProgression-free survivalP value
HR95%CIHR95%CI
CHOP cohort(n = 175)
 RDW > 14.35%2.1231.183–3.8120.012  0.502
 age > 603.4491.777–6.6920.0003.4342.093–5.6340.000
 Ann Arbor stage III/IV3.1551.702–5.8470.0002.8141.785–4.4360.000
R-CHOP cohort(n = 174)
 PLT126.5(×109/L)3.3441.491–7.5040.0033.0761.653–5.7230.000
 age > 602.3441.090–5.0390.029  0.333
 IPI > 22.3041.061–5.0020.035  0.322
 Extranodal sites> 1  0.7722.3471.371–4.0200.002